

# LIGHT·AI

## Detecting Infectious Diseases Instantly

Applying AI to smartphone images to identify disease in seconds – a patented, app-based solution.

January 2025



# Disclaimer

This corporate presentation of Light AI Inc. (the “Company”) and the information contained herein (the “Presentation”) is for informational purposes and is not an offer to sell or solicitation of an offer to buy securities of the Company and may not be relied upon in connection with the purchase or sale of securities. Recipients of this Presentation who are considering acquiring securities of the Company are referred to the public filings made by the Company with Canadian securities regulatory authorities, which are available under the Company’s SEDAR+ profile at [www.sedarplus.ca](http://www.sedarplus.ca). Information disclosed in this Presentation is current as of January 9 2025, except as otherwise provided herein, and the Company does not undertake or agree to update this Presentation after the date hereof. This Presentation contains forward-looking statements with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “potential” and similar expressions.

Forward-looking statements contained in this Presentation and other forward-looking statements are based on management of the Company’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this Presentation may include, but are not limited to statements with respect to: the Company’s intentions, plans and future actions; the business and future activities of the Company and anticipated developments in the operations of the Company; the performance of the Company’s business and operations; the length of time required to obtain permits, certifications and approvals; the Company’s expected reliance on key management personnel, advisors and consultants; expectations regarding trends in the healthcare industry; results and expectation concerning various partnerships, strategic alliances, projects and marketing strategies of the Company; and the economy generally. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and

actual results may differ materially from those in the forward-looking statements. Readers are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements based on certain risk factors including: the Company has limited operating history, which makes it difficult to evaluate the Company’s business prospects; the Company’s financial position and results of operations may differ materially from expectations; the management of the Company has limited experience managing a publicly-traded company; the Company expects to incur future losses and may never generate revenues; the Company may be unable to generate revenues or establish a subscription-based revenue model; the Company expects to require additional capital to support its business; the Company may never achieve profitability; the Company’s dependent on senior management team and key employees; the Company’s market opportunity and cost saving estimates are subject to significant uncertainty which may prove to be inaccurate; the Company may face growth-related risks; the Company could incur material losses relating to cyber-attacks or other information security breaches in the future; the risks associated with operating in a complex healthcare and technology regulatory and legal environment subject to a wide variety of laws and regulations, including those relating to provision of healthcare, consumer products, product liability and consumer protection; those relating to negligence; those relating to the manner in which the Company advertises, markets and sells products and services; labour and employment laws, including wage and hour laws; tax laws or interpretations thereof; data protection and privacy laws and regulations; the Company may face competition in its industry; the Company may be unable to adequately protect its proprietary and intellectual property rights; the Company’s reliance on obtaining and maintain regulatory approval in jurisdictions where its products or technologies are being researched, developed or commercialized; unfavorable global economic and political conditions could adversely affect the Company’s business, financial condition or results of operations; and other risks.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements contained in this Presentation or in certain of the other documents on file with Canadian securities regulatory authorities, which are available on the Company’s SEDAR+ profile at [www.sedarplus.ca](http://www.sedarplus.ca). The Company and its directors, officers and employees each disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue

reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

## Market & Industry Data

This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

## Trademarks

This presentation includes certain trademarks that are protected under applicable intellectual property laws and are the property of the Company. Solely for convenience, these trademarks may appear without the ® or TM symbol, but such references are not intended to indicate, in anyway, that the Company will not assert its rights to these trademarks to the fullest extent under applicable law. This presentation also contains trademarks of third parties which are the property of their respective owners. The use or display of these third parties’ trademarks is not intended to, and does not imply, a relationship with the Company, or an endorsement or sponsorship by or of the Company.

## U.S. Securities Law

This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available, information concerning the assets and operations of the Company included in this Presentation has been prepared in accordance with Canadian standards and is not comparable in all respects to similar information for United States companies.

**No securities regulatory authority has expressed an opinion about these securities and it is an offense to claim otherwise.**

# Light AI is addressing two of the pressing public health issues of our time

## 1. Antimicrobial resistance

**Antimicrobial resistance from misuse and overuse of antibiotics is consistently listed as one of the top global public health and development threats\***

\*Source: WHO named Antibiotic resistance as one top 10 Global Threats - <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>



## 2. Strep A

**Strep A infects more than 600M people globally every year\*, killing as many children as malaria\*\*.**

Source:

\* <https://www.nature.com/articles/s41541-023-00646-6>

\*\*<https://www.who.int/news-room/fact-sheets/detail/malaria>



**In the United States, for every 10 sore throats treated by a physician, there are 6 antibiotic prescriptions written, yet only 2 are actually bacterial infections.**

Adoption of LightAI's smartphone diagnostic for Strep A would mean that only the people who need antibiotics would get them.

# Light AI Highlights

Massive infectious footprint + Instant screening results =  
**Hyper scale growth opportunity**

## AI Platform

Paradigm shift: Light AI has patented an AI platform to detect infectious diseases by analyzing smartphone images in seconds. Initial target Strep A. Proprietary cloud-based library of 300,000 images.

## Simple to Use

The user opens an app on a smartphone and follows basic instructions that include accessing the camera. The process takes ~45 seconds and ~10 seconds to analyze the image in the cloud.

## Capital, Time, Partners

LightAI has raised over \$36M (not including SRED), and it has taken 8 years and 13 partners to get Light AI where it is today.

## Hyper Scale Growth Potential

No swabs, labs or proprietary hardware required— just a smartphone. Leveraging massive global smartphone footprint to manage a global infectious disease problem.

## AI Veterans and Healthcare Luminaries


From organizations such as Johnson & Johnson, Medtronic, Bristol Meyers Squibb, the CDC and WHO. Peter Whitehead, Light AI's founder and CEO, is the inventor of the VELScope. The VELScope has been used in over 50M oral health examinations by over 10,000 dental clinics in 23 countries.

## Commercial Ready

Multiple Go-To-Market paths, including the joint venture with TC4A to launch in lower middle income countries.

# An Iteratively Improving AI Model

(Multiple Validation Studies)



# Leadership

We continue to expand our impact with a team of multidisciplinary experts - across healthcare, technology - steadfast in our belief that technology should serve humanity

## Officers

**Peter Whitehead**

CEO

**George Reznik**

CFO and Corporate Secretary

**Thomas Scarnecchia**

COO

## Advisors

**Anthony Schaller**

**David Talan**

**Yu Zhao**

**Raymond Ng**

**David Bell**

## Board

**Steven Semmelmayer**

Chair

**Mark Attanasio**


**Hugh Cleland**

**Emmanuel Blin**

# Problem

## Current Medical Diagnostics System

24-72+ Hours



## Light AI

Immediate (On demand)

### Antibiotic Misuse







10/10 have indication 6/10 receive antibiotics



Only 2 or 3 out of 10 need antibiotics <sup>5 6</sup>



# How it works | identifies infection within seconds



## Contact HCP

Patient and healthcare provider meet over a telemedicine session. Symptoms are captured.

**\*Healthcare provider**

## Scan Session Initiated

The patient is prompted to scan their throat. Light AI technology automatically identifies biomarkers to analyze.

## Scan Analysis

Light AI immediately analyzes the scan data and returns results within seconds.

## On-Demand

Decision support that is immediately accessible, real time, inexpensive, non-invasive, pain free and accurate.

# Strep A | Light AI addresses major unmet needs

## Need for Urgency

Strep requires timely test results due to the potential health implications and the urgent need for treatment.

## Costly Infrastructure

Common tests like a throat swab require testing capabilities which are expensive and limited in many countries.

## Low POC Accuracy

A doctor cannot accurately identify Strep through a visual assessment unlike other conditions such as skin lesions.

## Patient Inconvenience

With only two or three out of ten tests showing a bacterial infection, most doctor visits are unnecessary, and could be avoided with digital screening.

## High Patient Volume

Very few conditions have the global reach of Strep, with Group A Strep infecting more than 600 million people globally.

# Go-To-Market paths | LMIC

- **LMIC\* distribution partner is TC4A (Tech Care For All).**
- **TC4A is a digital health platform with 120,000 healthcare practitioners in >20 countries.**
- **TC4A CEO and Founder, Emmanuel Blin, is a board member of Light AI. Mr. Blin is the former Chief Strategy Officer of Bristol Myers Squibb.**
- **Initial focus on Kenya and Uganda healthcare providers.**
- **Based on results, roll out to other LMIC markets.**

\*LMIC (Lower Middle Income Countries)

## Screening Product

### Development Objectives:

- Develop Android App in addition to existing iOS App
- Demonstrate functionality for pilot programs
- Design and implementation of prototype

### Regulatory Requirements:

- Expand and complete clinical studies in Kenya, Uganda, Nigeria and South America
- Registration, implementation and commercialization in Kenya, Uganda, Nigeria and South America

### Commercialization Path:

- Conduct feasibility pilot/study in Kenya
- Expand to 16 countries

Existing Partnerships



# Go-To-Market paths | wellness (DTC)

- **Wellness (DTC) is expected to be Light AI's largest market.**
- **Leverage large distribution ecosystems such as major smartphone.**
- **No FDA approvals required.**
- **Creating pilot programs.**

## Wellness Product

### Development Objectives:

- Modify existing app for the wellness market

### Regulatory Requirements:

- None

### Commercialization Path:

- Complete wellness market research
- Identify appropriate commercial partners

# Go-To-Market paths | FDA commercialization plan

## Clear FDA Pathway

- De Novo Application
- New device category: SaMD (Software as a Medical Device)
- AI/ML-powered POC (Point-of-care) diagnostic software for rapid detection of Group A Strep
- Pre-submission meetings with FDA have taken place to confirm regulatory pathway and Clinical Study protocol

## Clinical Trial

- Single pivotal clinical trial
- Strong Clinical Dev Partner
  - Carelon Research (Elevance Health)



## Launch Plan

- Reimbursement Available
  - Expected to be available
  - subject to FDA approval
- Distribution Channel
  - B2B to HCPs
- Discussions with Global distribution partners




# Anticipated timeline



2024

2025

2026



\*The timing associated with obtaining FDA approval depends heavily on the outcome of the prior clinical studies of the Company and feedback from the FDA, as applicable. The anticipated timeline provided herein is inherently speculative, subject to uncertainty and based on the Company's estimates only. Actual timing may vary materially from the disclosure provided herein.

# Light AI granted & allowed patents

Grant Date: Jun 2022

Grant Date: Mar 2023

Intention to Grant: May 2024

Grant Date: Nov 2024

## Patent 1

Image processing of streptococcal infection in pharyngitis subjects

US11369318B2  
United States

## Patent 2

Image processing of streptococcal infection in pharyngitis subjects

US11602312B2  
United States

## Patent 3

Image processing of streptococcal infection in pharyngitis subjects

EU19871128.5  
European Union

## Patent 4

Infection Detection Using Image Data Analysis

35100-48364/US  
United States

In addition, 1 patent granted in Australia and 4 other patents pending (2 in Canada, 1 in Europe, 1 in Israel).

Light AI's patents can be broadly characterized as having patented a method to diagnose disease that uses AI algorithms to process images obtained with cameras (including smartphones).

Light AI has one European divisional patent application, one Israeli patent application, one Canadian patent application, and one Hong Kong patent application filed with respect to the Image Processing of Streptococcal Infection in Pharyngitis Subjects. Light AI has one US continuation patent application, one Canadian patent application, and one European Union patent application filed in respect of the Infection Detection Using Image Data Analysis.

Specific claims about StrepA have also been granted.

# CAP table

## Light AI Inc Capitalization Table

<b>Common Shares issued and outstanding</b>	<b>116,230,671</b>
<b>Stock Options</b>	7,113,945
<b>Warrants</b>	24,085,595
<b>Broker Warrants</b>	2,546,860
<b>Fully Diluted</b>	149,977,071

**LIGHT·AI**

**Thank you**

**Peter Whitehead**  
CEO & Founder Light AI  
info@light.ai

**Sheldon Chang**  
sheldon@commoditypartners.ca

**Commodity Partners**  
604-687-7130

# References

1 - Ten threats to global health in 2019. World Health Organization.

[www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019](http://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019).

2 - Torotice D., Ferranna M., Bloom D. (2023). Optimal global spending for group A Streptococcus vaccine research and development. *npj Vaccines* 8(1), 62. <https://doi.org/10.1038/s41541-023-00646-6>.

3 - Miller, K. M., Carapetis, J. R., Van Beneden, C. A., Cadarette, D., Daw, J. N., Moore, H. C., Bloom, D. E., & Cannon, J. W. (2022). The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis. *EClinicalMedicine*, 48, 101458.

4 - Fact sheet: Antimicrobial resistance. World Health Organization.

[who.int/news-room/fact-sheets/detail/antimicrobial-resistance](http://who.int/news-room/fact-sheets/detail/antimicrobial-resistance).

5 - Shulman, S. T., Bisno, A. L., Clegg, H. W., Gerber, M. A., Kaplan, E. L., Lee, G., Martin, J. M., & Van Beneden, C. (2012). Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 55(10), 1279–1282. <https://doi.org/10.1093/cid/cis847>.

6 - Barnett, M. L., & Linder, J. A. (2014). Antibiotic prescribing to adults with sore throat in the United States, 1997-2010. *JAMA internal medicine*, 174(1), 138–140. <https://doi.org/10.1001/jamainternmed.2013.11673>.